Blood Clotting is the physiological process by which liquid blood changes into a stable clot following vascular injury. It is part of haemostasis, which limits blood loss while preserving normal circulation elsewhere. Haemostasis involves coordinated vascular responses, platelet activity and coagulation reactions that ultimately generate fibrin, a protein forming a mesh that stabilises the developing clot. The process must be tightly regulated because insufficient clotting can cause bleeding, whereas excessive or inappropriate clotting can obstruct blood vessels. Blood Clotting is therefore a balance between procoagulant, anticoagulant and fibrinolytic mechanisms rather than a simple on-or-off reaction.
Following vessel injury, local blood-vessel constriction can reduce blood flow and platelets adhere to exposed components of the damaged vessel wall. Activated platelets change shape, release signalling molecules and recruit additional platelets, producing a temporary platelet plug. Coagulation reactions then generate thrombin, which converts soluble fibrinogen into insoluble fibrin. Fibrin strands reinforce the platelet plug and produce a more stable clot. Calcium ions, phospholipid surfaces and multiple coagulation proteins participate in these reactions. The sequence is interconnected rather than strictly linear, with amplification mechanisms rapidly increasing thrombin generation at the site of injury.
The coagulation system is traditionally described using intrinsic and extrinsic pathways that converge on a common pathway, although modern models emphasise cell-based interactions between coagulation factors and cellular surfaces. Tissue factor exposure initiates an important pathway following tissue injury, while contact-related mechanisms contribute to laboratory measurements and particular physiological processes. Activated factor X contributes to conversion of prothrombin into thrombin, and thrombin has multiple functions, including fibrin generation and activation of additional coagulation components and platelets. Factor XIII subsequently helps stabilise fibrin by cross-linking it. This network allows local amplification while regulatory mechanisms limit clot extension.
Blood Clotting must be controlled to prevent unnecessary thrombosis. Natural anticoagulant systems include antithrombin, the protein C and protein S system and tissue factor pathway inhibition. Fibrinolysis provides a mechanism for removing clots after repair, with plasmin breaking down fibrin into degradation products. Endothelial cells also contribute to an anticoagulant surface under normal conditions and can release substances that influence platelet activity and vascular tone. The balance between coagulation and fibrinolysis changes in disease, injury, pregnancy, surgery, immobility and other physiological circumstances. Disruption can produce either bleeding or thrombosis.
Laboratory assessment of Blood Clotting commonly uses tests such as prothrombin time and activated partial thromboplastin time, although these tests measure selected parts of the coagulation system and do not represent the complete physiological process. Platelet count, fibrinogen concentration and specific factor assays can provide additional information when indicated. Prothrombin time is particularly useful for monitoring certain anticoagulant treatments and investigating abnormalities involving particular coagulation factors, while activated partial thromboplastin time can help investigate other abnormalities and monitor some anticoagulant therapies. Test interpretation requires knowledge of medications, liver function, clinical context and specimen quality.
Inherited abnormalities can impair Blood Clotting. Haemophilia A results from deficiency or dysfunction of factor VIII, while haemophilia B involves factor IX. Von Willebrand disease involves quantitative or qualitative abnormalities of von Willebrand factor and can affect platelet adhesion as well as factor VIII stability. Acquired problems can result from liver disease, vitamin deficiencies, severe illness, anticoagulant medicines or consumption of coagulation factors. Bleeding severity does not always correlate directly with a single laboratory value because different defects affect different stages of haemostasis and compensatory mechanisms vary between individuals.
Excessive Blood Clotting can produce thrombosis, in which a clot forms within a blood vessel and obstructs circulation. A venous clot can produce deep vein thrombosis and may embolise to the lungs, while arterial thrombosis can contribute to events such as myocardial infarction or ischaemic stroke. Risk is influenced by factors traditionally described through abnormal blood flow, vessel-wall changes and increased coagulability. Anticoagulant medicines reduce clot formation through different mechanisms, whereas antiplatelet medicines primarily reduce platelet-mediated processes and are used for different clinical indications. These therapies can reduce thrombosis risk while simultaneously increasing bleeding risk.
Blood Clotting is sometimes incorrectly described as inherently harmful because clots can cause serious disease, but normal clotting is essential for survival after injury. Conversely, the presence of a clotting abnormality does not necessarily mean that a person will bleed continuously or develop thrombosis in every circumstance. Diagnosis requires integrating symptoms, family history, medication exposure, laboratory results and clinical circumstances. Modern understanding emphasises the interaction between coagulation, platelets, endothelium, inflammation and blood flow. This integrated system explains why clotting disorders can manifest differently and why treatment must target the specific mechanism responsible.
